Skip to Main Content

For some opioid makers, the financial outlook is painful.

Between falling prices for many of the medicines and fast-growing litigation, a few of these companies have only modest flexibility to cope with these mounting risks, according to a new analysis by Moody’s Investor Service. And the drug maker most likely to be impacted is Endo International (ENDP).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.